Clinical characteristics of myelin-oligodendrocyte glycoprotein antibody-positive pediatric autoimmune encephalitis without demyelination: A case series.

Front Immunol

Department of Neurology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, China.

Published: December 2022

Purpose: To facilitate the identification of myelin-oligodendrocyte glycoprotein (MOG) antibody-associated diseases in pediatric autoimmune encephalitis without demyelination, we explored the clinical characteristics of patients having MOG antibody-positive pediatric autoimmune encephalitis without demyelination in Children's Hospital of Chongqing Medical University, China.

Methods: We reviewed patients' medical records from January 2019 to June 2022 and retrospectively analyzed clinical manifestations, brain magnetic resonance imaging (MRI) findings, laboratory findings, treatments and outcomes of children with autoimmune encephalitis who tested positive for MOG antibodies in serum but for whom demyelination was not detected on MRI.

Results: Eighteen patients (6 boys, 12 girls; median age: 103.2 (range: 36-160) months) were included: 15 tested positive for MOG antibodies in both serum and cerebrospinal fluid (CSF); three tested positive only in serum. The most common clinical symptoms were altered mental status (18/18), fever (16/18), headache (14/18), seizures (6/18) and focal neurologic deficits (5/18). All patients had CSF pleocytosis (median count: 74/µL, range: 14-380/µL); five patients had elevated CSF protein levels (median: 0.85 g/L, range: 0.53-1.48 g/L) simultaneously. CSF glucose levels were normal in all patients. Abnormal electroencephalogram (EEG) results were found in 12 patients: generalized or focal slowing (9/12), focal epileptic discharges (2/12), and generalized slowing and focal epileptic discharges (1/12). Twelve of the 18 patients showed hyperintense T2-weighted lesions on brain MRI in the cortex (6), basal ganglia (5), thalamus (3), cerebellum (4), and brainstem (2). All patients received immunotherapy and had favorable outcomes at discharge (modified Rankin scale score: <2). Three children relapsed once; however, all children had good outcomes at the last follow-up.

Conclusion: MOG antibody-positive pediatric autoimmune encephalitis without demyelination is mainly characterized by prolonged fever, altered mental status, headache, mild-to-moderate increase in cell count in the CSF, and normal or abnormal brain MRI, which may involve any part outside the white matter without specificity. All patients with MOG antibody-positive pediatric autoimmune encephalitis without demyelination had favorable outcomes after immunotherapy, while a few patients relapsed once.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751181PMC
http://dx.doi.org/10.3389/fimmu.2022.1050688DOI Listing

Publication Analysis

Top Keywords

autoimmune encephalitis
16
pediatric autoimmune
12
encephalitis demyelination
12
tested positive
12
clinical characteristics
8
myelin-oligodendrocyte glycoprotein
8
antibody-positive pediatric
8
patients
8
positive mog
8
mog antibodies
8

Similar Publications

Virus encephalitis (VE), recognized as one of the common kinds of central nervous system (CNS) diseases after virus infection, has a surprising correlation with autoimmune encephalitis (AE) when autoimmune antibodies emerge in cerebrospinal fluid (CSF) or serum. Herpes simplex virus and Epstein-Barr virus are the most critical agents worldwide. By molecular mimicry, herpes viruses can invade the brain directly or indirectly.

View Article and Find Full Text PDF

Objective: To analyze the subjective sleep assessment in patients with neuromyelitis optica spectrum diseases (NMOSD) according to the current disease criteria of 2015.

Material And Methods: Twenty patients (17 women and 3 men), median age 44.5 years [Q:Q=27.

View Article and Find Full Text PDF

Objective: To study the quality of life (QoL) of patients with multiple sclerosis (MS) in the Smolensk region who receive MS disease-modifying therapies (DMT).

Material And Methods: The study included 37 patients receiving MS DMT. The 36-Item Short Form Health Survey (SF-36), the Multiple sclerosis Quality of Life (MusiQol), the Hamilton Depression Rating Scale, a scale of satisfaction with treatment, the Fatigue Severity Scale were administered.

View Article and Find Full Text PDF

New autoimmune disorder development after immune reconstitution therapy for multiple sclerosis.

Sci Rep

December 2024

Clinic of Neurology and Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Immune reconstitution therapy (IRT) is a relatively new and highly effective treatment option for multiple sclerosis (MS). Uncertainty regarding the development of autoimmune disorders (ADs) after some therapies remains. The aim of this study was to assess new AD development after IRT in MS patients and to describe the nature of those ADs and the time to onset.

View Article and Find Full Text PDF

Importance: A growing body of literature suggests the presence of a prodromal period with nonspecific signs and symptoms before onset of multiple sclerosis (MS).

Objective: To systematically assess diseases and symptoms diagnosed in the 5 years before a first MS- or central nervous system (CNS) demyelinating disease-related diagnostic code in pediatric patients compared with controls without MS and controls with another immune-mediated disorder, juvenile idiopathic arthritis (JIA).

Design, Setting, And Participants: This population-based, matched case-control study included children and adolescents (aged <18 years) in Germany with statutory health insurance from January 2010 to December 2020.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!